In a recent preclinical study by Paez-Ribes et al., we had shown in the resected orthotopic LM2-4 breast cancer model that DC101 (VEGFR2-specific inhibition) was unable to improve OS when added to adjuvant paclitaxel chemotherapy23. Here, KDR is linked to breast carcinoma.